RB1 and phyllodes tumor: This genomic quiescence confirms that FAs do not require large-scale structural alterations for tumorigenesis and distinguishes them from phyllodes tumors, which typically acquire CNAs involving oncogenes (EGFR, PDGFB) or tumor suppressors (TP53, RB1).